EGFR and non-small cell lung carcinoma: Our results show that around 25% of patients with EGFR WT or unknown (Unk) non-squamous NSCLC overexpress c-Met protein, vs 3–5% of patients who harbor MET exon 14 skipping mutations or have MET gene amplification, strongly indicating that the development of treatments for c-Met protein–overexpressing NSCLC may improve outcomes for these patients.